Dasatinib-Teva
Dasatinib-Teva is a generic from Teva Pharma AG and is listed on the FOPH Specialities List. Basic health insurance reimburses it within the authorised indication. The public price ranges from CHF 543.25 to CHF 1'215.45 depending on the pack; the co-payment is 10 per cent.
Core data
- Authorisation holder
- Teva Pharma AG
- ATC code
- L01EA02
- IT group
- 07.16.10 Cytostatica
- Active substances
- Dasatinibum
- Preparation type
- Generic
- On the SL since
- 01/12/2022
- Last price change
- 01/04/2024
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Filmtabl 20 mg | Blist 60 Stk | CHF 484.40 | CHF 543.25 | 01/12/2022 | A | 7680671000115 |
| Filmtabl 50 mg | Blist 60 Stk | CHF 1'072.75 | CHF 1'183.10 | 01/12/2022 | A | 7680671000122 |
| Filmtabl 70 mg | Blist 60 Stk | CHF 1'072.75 | CHF 1'183.10 | 01/12/2022 | A | 7680671000139 |
| Filmtabl 100 mg | Blist 30 Stk | CHF 1'102.52 | CHF 1'215.45 | 01/12/2022 | A | 7680671000092 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
Behandlung von Patienten mit Philadelphiachromosom-positiver chronischer myeloischer Leukämie (Ph+CML) in der chronischen Phase bei Progression oder Resistenz auf optimale Imatinib-Dosierung, in der akzelerierten Phase oder Blastenkrise bei Progression oder Resistenz auf Imatinib.
Behandlung von Patienten mit Philadelphiachromosom-positiver chronischer myeloischer Leukämie (Ph+CML) in der chronischen Phase, der akzelerierten Phase oder Blastenkrise bei signifikanter Toxizität unter Therapie mit Imatinib.
More preparations in this group
FAQ
Is Dasatinib-Teva covered by Swiss health insurance?
Yes, but only under conditions. Dasatinib-Teva is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Dasatinib-Teva cost in Switzerland?
The public price is the maximum price set by the FOPH and for Dasatinib-Teva ranges from CHF 543.25 to CHF 1'215.45 per pack. The ex-factory price ranges from CHF 484.40 to CHF 1'102.52. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages